Click on a filter below to refine your search. Remove a filter to broaden your search.
The findings were seen regardless of vaccination status and history of prior infection.
The reduction in risk was greatest for those with a history of ischemic heart disease or stroke.
A mortality prediction may help guide treatment and advance care planning for community-dwelling older adults with dementia.
An increased incidence of myocardial infarction and pulmonary embolism were seen in the second week after first dose of Oxford-AstraZeneca vaccine.
Only 4 and 9% of this effect was mediated by atrial fibrillation or stroke, respectively.
However, from 13 to 52 weeks after COVID-19, no increase was seen for diabetes mellitus or cardiovascular disease.
The clinical lexicon presents data elements related to cardiovascular and noncardiovascular complications of COVID-19.
An increased risk for incident cardiovascular disease also was observed among those not hospitalized during acute phase.
And one in four COVID-19 survivors says the virus affected their heart health.
One-year outcomes were similar for patients with or without Alzheimer’s disease and related dementias.